Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).
Wright David M, Konstantakopoulou Evgenia, Montesano Giovanni, Nathwani Neil, Garg Anurag, Garway-Heath David, Crabb David P, Gazzard Gus, Adeleke Mariam, Ambler Gareth
AI Summary
This study found that initial selective laser trabeculoplasty (SLT) led to less visual field progression in glaucoma/ocular hypertension patients compared to initial medical therapy, suggesting SLT may be a better first-line option.
Abstract
Purpose
To compare visual field outcomes of ocular hypertensive and glaucoma patients treated first with medical therapy with those treated first with selective laser trabeculoplasty (SLT).
Design
Secondary analysis of patients from the Laser in Glaucoma and Ocular Hypertension study, a multicenter randomized controlled trial.
Participants
Three hundred forty-four patients (588 eyes) treated first with medical therapy and 344 patients (590 eyes) treated first with SLT.
Methods
Visual fields (VFs) were measured using standard automated perimetry and arranged in series (median length and duration, 9 VFs over 48 months). Hierarchical linear models were used to estimate pointwise VF progression rates, which were then averaged to produce a global progression estimate for each eye. Proportions of points and patients in each treatment group with fast (<-1 dB/year) or moderate (<-0.5 dB/year) progression were compared using log-binomial regression.
Main outcome measures
Pointwise and global progression rates of total deviation (TD) and pattern deviation (PD).
Results
A greater proportion of eyes underwent moderate or fast TD progression in the medical therapy group compared with the SLT group (26.2% vs. 16.9%; risk ratio [RR], 1.55; 95% confidence interval [CI], 1.23-1.93; P < 0.001). A similar pattern was observed for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001). A greater proportion of pointwise PD rates were categorized as moderate or fast in the medical therapy group (medical therapy, 11.5% vs. SLT, 8.3%; RR, 1.39; 95% CI, 1.32-1.46; P < 0.001). No statistical difference was found in the proportion of eyes that underwent moderate or fast PD progression (medical therapy, 9.9% vs. SLT, 7.1%; RR, 1.39; 95% CI, 0.95, 2.03; P = 0.0928).
Conclusions
A slightly larger proportion of ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared with those treated first with SLT.
MeSH Terms
Shields Classification
Key Concepts5
A greater proportion of eyes underwent moderate or fast total deviation (TD) progression in the medical therapy group (26.2%) compared with the selective laser trabeculoplasty (SLT) group (16.9%) in ocular hypertensive and glaucoma patients, with a risk ratio (RR) of 1.55 (95% confidence interval [CI], 1.23-1.93; P < 0.001).
A greater proportion of pointwise total deviation (TD) rates were categorized as moderate or fast in the medical therapy group (26.1%) compared to the selective laser trabeculoplasty (SLT) group (19.0%) in ocular hypertensive and glaucoma patients, with a risk ratio (RR) of 1.37 (95% CI, 1.33-1.42; P < 0.001).
A greater proportion of pointwise pattern deviation (PD) rates were categorized as moderate or fast in the medical therapy group (11.5%) compared to the selective laser trabeculoplasty (SLT) group (8.3%) in ocular hypertensive and glaucoma patients, with a risk ratio (RR) of 1.39 (95% CI, 1.32-1.46; P < 0.001).
No statistical difference was found in the proportion of eyes that underwent moderate or fast pattern deviation (PD) progression between the medical therapy group (9.9%) and the selective laser trabeculoplasty (SLT) group (7.1%) in ocular hypertensive and glaucoma patients (RR, 1.39; 95% CI, 0.95, 2.03; P = 0.0928).
Ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid visual field progression in a slightly larger proportion compared with those treated first with selective laser trabeculoplasty (SLT).
Related Articles5
The effect of treatment on progression of glaucoma.
Clinical TrialVisual Field Changes in Diabetic Retinopathy: Natural History and after Pan-Retinal Photocoagulation in the Diabetic Retinopathy Study and the ETDRS.
Cohort StudyThe Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development.
Randomized Controlled TrialThe Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group.
Randomized Controlled TrialSix-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.